Signal active
Organization
Contact Information
Overview
AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure.
About
Biotechnology, Medical, Biopharma
2017
1-10
Headquarters locations
Solna, Stockholms Lan, Sweden, Europe
Social
Profile Resume
AnaCardio headquartered in Europe, operates in the Biotechnology, Medical, Biopharma sector. The company focuses on Biotechnology and has secured $635.0M in funding across 36 round(s). With a team of 1-10 employees, AnaCardio is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - AnaCardio, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.
Employees
N/A
Funding Rounds
3
1
0
$17.6M
Details
2
AnaCardio has raised a total of $17.6M in funding over 2 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2022 | Early Stage Venture | 14.0M | ||
2021 | Seed |
Investors
AnaCardio is funded by 15 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
AnnHelene Ljungström | - | FUNDING ROUND - AnnHelene Ljungström | 3.6M |
Viktor Drvota | - | FUNDING ROUND - Viktor Drvota | undefined |
AnaCardio | - | FUNDING ROUND - AnaCardio | undefined |
Karolinska | - | FUNDING ROUND - Karolinska | undefined |
Recent Activity
News
Sep 17, 2024
Cision - AnaCardio successfully completes first part of AC01 HFrEF study and provides a clinical update
News
Jun 03, 2024
Cision - Michael Grissinger appointed as new Chairman of AnaCardio
News
Jan 17, 2024
GlobeNewswire News Room - Karolinska Development’s portfolio company AnaCardio secures SEK 50 million as part of its Series A investment round
Funding Round
Sep 07, 2022
AnaCardio raised $14012919 on 2022-09-07 in Series A
Funding Round
Feb 03, 2022
AnaCardio raised $3626423 on 2022-02-03 in Debt Financing
Funding Round
Jun 17, 2021
AnaCardio raised an undisclosed amount on 2021-06-17 in Seed Round